Genprex, Inc.
GNPX · Nasdaq · United States
Share price · GNPX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when GNPX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 17 Nov 2026-12.1%
Nothing announced by GNPX that day or the session before.
- 30 Oct 2026+9.8%
Nothing announced by GNPX that day or the session before.
- 28 Sep 2026-14.6%
Nothing announced by GNPX that day or the session before.
- 3 Aug 2026-20.7%
- 30 Jul 2026-14.9%
- 16 Jul 2026-25.9%
Nothing announced by GNPX that day or the session before.
- 14 Jul 2026-13.5%
- 18 Jun 2026+22.5%
- 15 Jun 2026-24.0%
- 23 Feb 2026+27.5%
Share of unusual movement by asset
For each asset, the share of GNPX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
Quaratusugene Ozeplasmid(Reqorsa) | Phase 1/2 | TUSC2 (tumor suppressor gene replacement)Gene therapy / editing | Non-Small Cell Lung CancerSmall Cell Lung Cancer |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $2.7M | $15M | $4.2M-$2.9M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $2.7M | $15M | $4.5M-$5.1M operating cash flow | report ↗ |
| 2026-Q1 | — | $2.8M | $18M | $4.5M-$3.1M operating cash flow | report ↗ |
| 2025-Q3 | — | $2.2M | $1.1M | $3.8M-$3.2M operating cash flow | report ↗ |
| 2025-Q2 | — | $2.5M | $1.4M | $4.7M-$3.9M operating cash flow | report ↗ |
| 2025-Q1 | — | $2.5M | $3.5M | $4.0M-$4.2M operating cash flow | report ↗ |
| 2024-Q3 | — | $2.8M | $1.5M | $4.3M-$2.2M operating cash flow | report ↗ |
| 2024-Q2 | — | $1.7M | $2.5M | $6.5M-$5.8M operating cash flow | report ↗ |
| 2024-Q1 | — | $3.3M | $8.2M | $6.0M-$5.3M operating cash flow | report ↗ |
| 2023-Q3 | — | $4.6M | $12M | $7.8M-$4.7M operating cash flow | report ↗ |
| 2023-Q2 | — | $4.0M | $10.0M | $8.0M-$8.1M operating cash flow | report ↗ |
| 2023-Q1 | — | $5.3M | $18M | $9.2M-$6.9M operating cash flow | report ↗ |
| 2022-Q3 | $0 | $3.6M | $26M | $6.1M-$4.6M operating cash flow | report ↗ |
| 2022-Q2 | $0 | $2.7M | $30M | $5.2M-$4.5M operating cash flow | report ↗ |
| 2022-Q1 | $0 | $1.9M | $35M | $5.7M-$4.1M operating cash flow | report ↗ |
| 2021-Q3 | $0 | $1.4M | $42M | $3.4M-$2.6M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $9.4M | $7.8M | $4.1M-$15M operating cash flow | report ↗ |
For FY2025, Genprex did not disclose revenue, and prior-year revenue was also not disclosed. R&D spend was $9.429M, down 10.5% YoY from $10.535M. Cash and equivalents totaled $7.831M. Net income/loss was not disclosed, and quarterly net burn was $16.229M.
The company continued enrolling the Phase 2a expansion of Acclaim-1 (REQORSA plus Tagrisso) and the Phase 2 expansion of Acclaim-3 (REQORSA plus Tecentriq), with interim analyses expected in the second half of 2026; Acclaim-2 was closed to new enrollment. In diabetes, Genprex formed Convergen Biotech as a wholly-owned subsidiary to support separation of its diabetes program, and after a February 2026 FDA meeting it plans to advance preclinical and toxicology studies and cGMP manufacturing toward an IND. During 2025 the company effected reverse stock splits, raised approximately $10.8M in net proceeds through its ATM program, and regained Nasdaq compliance.
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 2 sales ($22). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-04-14 | LONGNECKER BRENT M · director | Open-market sale | 8 | $1.23 | $10 | Form 4 |
| 2026-04-14 | LONGNECKER BRENT M · director | Open-market sale | 10 | $1.23 | $12 | Form 4 |
| 2026-02-27 | Confer Ryan M. · director, President, CEO and CFO | Tax withholding | 9,330 | $2.00 | $19K | Form 4 |
| 2026-02-27 | Berger Mark Stanley · Chief Medical Officer | Tax withholding | 7,168 | $2.00 | $14K | Form 4 |
| 2025-12-22 | Wilson William R Jr. · director | Award / grant | 9,000 | — | — | Form 4 |
| 2025-12-22 | LONGNECKER BRENT M · director | Award / grant | 9,000 | — | — | Form 4 |
| 2025-12-22 | Confer Ryan M. · director, President, CEO and CFO | Award / grant | 45,000 | — | — | Form 4 |
| 2025-12-22 | Berger Mark Stanley · Chief Medical Officer | Award / grant | 28,500 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 27 reporting institutions held 0.1M shares ($156K, 11.4% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | GEODE CAPITAL MANAGEMENT, LLC | 33,372 | $60K |
| 2 | Mayflower Financial Advisors, LLC | 20,000 | $36K |
| 3 | MANCHESTER FINANCIAL INC | 20,000 | $36K |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 5,950 | $11K |
| 5 | JONES FINANCIAL COMPANIES LLLP | 2,105 | $4K |
| 6 | CITIGROUP INC | 2,039 | $4K |
| 7 | Cheviot Value Management, LLC | 1,000 | $2K |
| 8 | Sound Income Strategies, LLC | 1,000 | $2K |
| 9 | OSAIC HOLDINGS, INC. | 232 | $417 |
| 10 | Bernard Wealth Management Corp. | 200 | $362 |
| 11 | BlackRock, Inc. | 188 | $340 |
| 12 | HARBOUR INVESTMENTS, INC. | 120 | $218 |
| 13 | SBI Securities Co., Ltd. | 48 | $87 |
| 14 | HighMark Wealth Management LLC | 10 | $18 |
| 15 | MORGAN STANLEY | 6 | $11 |